Biogen Inc at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with Chris Viehbacher, who joined Biogen a little bit less than 2 months ago as CEO. So Chris, Happy New Year, and thanks for joining us today.
Thanks. Happy New Year to you.
Questions & Answers
So maybe just to kick off. It seems like you're joining a company that's kind of at a crossroads. So you've got, obviously, a very exciting new launch in the Alzheimer's side. We've got a large pipeline, but one I think is viewed as kind of high-risk high reward, and we've got a base business that's got some LOE pressures. So can you talk about the key challenges that you see facing Biogen right now and how your kind of plan to prioritize these as you think about your
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |